Pilocarpine Hydrochloride Ophthalmic Solution Recalled for Manufacturing Compliance Deviations
The FDA has recalled all lots of Pilocarpine Hydrochloride Ophthalmic Solution 4% due to manufacturing process deviations. The distributor ceased operations and cannot complete required stability testing.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall. Since no illnesses, injuries, or deaths are reported and the hazard is theoretical (inability to verify product stability), the score cannot exceed 3 per the rubric. This is scored as High (3) because the product represents a risk-of-harm where injury has not yet been reported—the incomplete stability studies mean the product's quality and safety cannot be verified over time.
Plain-English summary
The FDA has issued a Class II recall of Pilocarpine Hydrochloride Ophthalmic Solution, USP 4%, distributed in 15 mL bottles. All lots distributed nationwide in the United States and Puerto Rico are affected by this recall.
The recall was issued because Akorn, Inc., the manufacturing firm, went out of business. As a result, the firm could not continue Current Good Manufacturing Practice (CGMP) stability testing. Stability testing is necessary to verify the product maintains its strength, safety, and effectiveness throughout its shelf life.
Without completed stability testing, the FDA cannot verify that the product quality has been maintained over time. This is the reason all lots of this medication have been recalled.
The recalled product
- Product
- Pilocarpine Hydrochloride Ophthalmic Solution, USP 4%, 15 mL bottles, Rx Only, Sterile, Distributed by: Akorn Operating Company LLC, Gurnee, IL 60031. ALL NDCs
- Manufacturer
- Akorn, Inc.
- Category
- Drug
- Hazard
- stability-testing-incomplete
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27